Article: Anti-infective surgical therapy of peri-implantitis: a 12-month prospective clinical study
| Title | Anti-infective surgical therapy of peri-implantitis: a 12-month prospective clinical study | ||||||
|---|---|---|---|---|---|---|---|
| Authors | Heitz-Mayfield, LJA2 Salvi, GE5 Mombelli, A3 Faddy, M4 Lang, NP1 | ||||||
| Issue Date | 2012 | ||||||
| Publisher | Wiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CLR | ||||||
| Citation | Clinical Oral Implants Research, 2012, v. 23 n. 2, p. 205-210 [How to Cite?] DOI: http://dx.doi.org/10.1111/j.1600-0501.2011.02276.x | ||||||
| Abstract | AIM: The aim of this prospective cohort study was to evaluate an anti-infective surgical protocol for the treatment of peri-implantitis. MATERIALS AND METHODS: Thirty-six implants in 24 partially dentate patients with moderate to advanced peri-implantitis were treated using an anti-infective surgical protocol incorporating open flap debridement and implant surface decontamination, with adjunctive systemic amoxicillin and metronidazole. Treatment outcomes were assessed at 3, 6 and 12 months. Patient-based statistical analyses using multiple regression analyses were performed. RESULTS: There was 100% survival of treated implants at 12 months. At 3 months, there were statistically significant (P < 0.01) reductions in mean probing depths (PD), Bleeding on Probing (BoP) and suppuration. The greater the mean PD at baseline, the greater the PD reduction at 3 months. At 3 months, there was also a significant mean facial mucosal recession of 1 mm (P < 0.001). All these changes were maintained at 6 and 12 months. At 12 months, all treated implants had a mean PD < 5 mm, while 47% of the implants had complete resolution of inflammation (BoP negative). At 12 months, 92% of implants had stable crestal bone levels or bone gain. There were no significant effects of smoking on any of the treatment outcomes. CONCLUSIONS: For the treatment of peri-implantitis, an anti-infective protocol incorporating surgical access, implant surface decontamination and systemic antimicrobials followed by a strict postoperative protocol was effective at 3 months with the results maintained for up to 12 months after treatment. | ||||||
| Description | On behalf of the Implant Complication Research Group | ||||||
| ISSN | 0905-7161 2011 Impact Factor: 2.514 2011 SCImago Journal Rankings: 0.117 | ||||||
| DOI | http://dx.doi.org/10.1111/j.1600-0501.2011.02276.x | ||||||
| ISI Accession Number ID | WOS:000299098700010
Funding Information: This multicentre study was supported by a grant of the ITI Foundation for the Promotion of Implantology, Basel, Switzerland (ITI grant Nr. 341/04) and the Clinical Research Foundation (CRF) for The Promotion of Oral Health, Brienz, Switzerland (SKF/CRF grant Nr. 16/05. |
| dc.contributor.author | Heitz-Mayfield, LJA | ||||||
|---|---|---|---|---|---|---|---|
| dc.contributor.author | Salvi, GE | ||||||
| dc.contributor.author | Mombelli, A | ||||||
| dc.contributor.author | Faddy, M | ||||||
| dc.contributor.author | Lang, NP | ||||||
| dc.date.accessioned | 2012-02-28T01:52:59Z | ||||||
| dc.date.available | 2012-02-28T01:52:59Z | ||||||
| dc.date.issued | 2012 | ||||||
| dc.description.abstract | AIM: The aim of this prospective cohort study was to evaluate an anti-infective surgical protocol for the treatment of peri-implantitis. MATERIALS AND METHODS: Thirty-six implants in 24 partially dentate patients with moderate to advanced peri-implantitis were treated using an anti-infective surgical protocol incorporating open flap debridement and implant surface decontamination, with adjunctive systemic amoxicillin and metronidazole. Treatment outcomes were assessed at 3, 6 and 12 months. Patient-based statistical analyses using multiple regression analyses were performed. RESULTS: There was 100% survival of treated implants at 12 months. At 3 months, there were statistically significant (P < 0.01) reductions in mean probing depths (PD), Bleeding on Probing (BoP) and suppuration. The greater the mean PD at baseline, the greater the PD reduction at 3 months. At 3 months, there was also a significant mean facial mucosal recession of 1 mm (P < 0.001). All these changes were maintained at 6 and 12 months. At 12 months, all treated implants had a mean PD < 5 mm, while 47% of the implants had complete resolution of inflammation (BoP negative). At 12 months, 92% of implants had stable crestal bone levels or bone gain. There were no significant effects of smoking on any of the treatment outcomes. CONCLUSIONS: For the treatment of peri-implantitis, an anti-infective protocol incorporating surgical access, implant surface decontamination and systemic antimicrobials followed by a strict postoperative protocol was effective at 3 months with the results maintained for up to 12 months after treatment. | ||||||
| dc.description.nature | Link_to_subscribed_fulltext | ||||||
| dc.description | On behalf of the Implant Complication Research Group | ||||||
| dc.identifier.citation | Clinical Oral Implants Research, 2012, v. 23 n. 2, p. 205-210 [How to Cite?] DOI: http://dx.doi.org/10.1111/j.1600-0501.2011.02276.x | ||||||
| dc.identifier.doi | http://dx.doi.org/10.1111/j.1600-0501.2011.02276.x | ||||||
| dc.identifier.epage | 210 | ||||||
| dc.identifier.hkuros | 198615 | ||||||
| dc.identifier.isi | WOS:000299098700010
Funding Information: This multicentre study was supported by a grant of the ITI Foundation for the Promotion of Implantology, Basel, Switzerland (ITI grant Nr. 341/04) and the Clinical Research Foundation (CRF) for The Promotion of Oral Health, Brienz, Switzerland (SKF/CRF grant Nr. 16/05. | ||||||
| dc.identifier.issn | 0905-7161 2011 Impact Factor: 2.514 2011 SCImago Journal Rankings: 0.117 | ||||||
| dc.identifier.issue | 2 | ||||||
| dc.identifier.pmid | 22092831 | ||||||
| dc.identifier.scopus | eid_2-s2.0-84855919545 | ||||||
| dc.identifier.spage | 205 | ||||||
| dc.identifier.uri | http://hdl.handle.net/10722/145507 | ||||||
| dc.identifier.volume | 23 | ||||||
| dc.language | eng | ||||||
| dc.publisher | Wiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CLR | ||||||
| dc.publisher.place | United States | ||||||
| dc.relation.ispartof | Clinical Oral Implants Research | ||||||
| dc.rights | The definitive version is available at www3.interscience.wiley.com | ||||||
| dc.subject.mesh | Amoxicillin - therapeutic use | ||||||
| dc.subject.mesh | Anti-Bacterial Agents - therapeutic use | ||||||
| dc.subject.mesh | Debridement - methods | ||||||
| dc.subject.mesh | Decontamination - methods | ||||||
| dc.subject.mesh | Peri-Implantitis - surgery | ||||||
| dc.title | Anti-infective surgical therapy of peri-implantitis: a 12-month prospective clinical study | ||||||
| dc.type | Article |
Author Affiliations
- The University of Hong Kong
- University of Western Australia
- Université de Genève
- Queensland University of Technology
- Universität Bern